Interpreting GLP ‐ 1RA Cost‐Effectiveness: A Call for Caution
Author:
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesityObesity, 2025
- Growth and changing landscape of the cost-utility literature: an Australian perspective, 1992-2022Health Policy, 2025
- Discontinuation of Glucagon-Like Peptide-1 Receptor AgonistsJAMA, 2025